DeAnne Stolarik
AbbVie (United States)(US)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Hepatitis C virus research, HIV/AIDS drug development and treatment, Hormonal Regulation and Hypertension, Drug Solubulity and Delivery Systems
Most-Cited Works
- → Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors(2015)262 cited
- → Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport(2018)155 cited
- → Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease(2021)77 cited
- → Discovery and Metabolic Stabilization of Potent and Selective 2-Amino-N-(adamant-2-yl) Acetamide 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors(2006)77 cited
- → Adamantane sulfone and sulfonamide 11-β-HSD1 Inhibitors(2006)64 cited
- → Amorphous solid dispersions of enzalutamide and novel polysaccharide derivatives: investigation of relationships between polymer structure and performance(2020)61 cited
- → The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class(2002)60 cited
- → Highlights of the Structure–Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530)(2018)53 cited
- → Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis In Vivo(2023)45 cited
- Pharmacokinetics of sustained-release and transdermal buprenorphine in Göttingen minipigs (Sus scrofa domestica).(2014)